newsAs part of the agreement, AC Immune SA will be…
14 May 2024 | By Catherine Eckford (European Pharmaceutical Review)
As part of the agreement, AC Immune SA will be eligible for an option exercise fee and extra potential milestones of up to approximately $2.1 billion from Takeda.